Results 1 to 10 of about 5,310 (212)

Thiopurine S-methyltransferase activity in Nigerians: phenotypes and activity reference values [PDF]

BMC Research Notes, 2018
Objectives This study assessed the activity of thiopurine S-methyltransferase (TPMT) in Nigerians with a view to providing data on susceptibility to thiopurine toxicity, and as well generate reference activity values for clinical use.
Ayorinde Adehin, Oluseye O. Bolaji
doaj   +2 more sources

Polymorphisms of the thiopurine S-methyltransferase gene among the Libyan population [PDF]

Libyan Journal of Medicine, 2015
Background: Thiopurine S-methyltransferase (TPMT) is a cytosolic enzyme that catalyses the S-methylation of 6-mercaptopurine and azathioprine. Low activity phenotypes are correlated with polymorphism in the TPMT gene.
Hamza Ben Zeglam, Abdrazak Benhamer, Adel Aboud, Haitem Rtemi, Meftah Mattardi, Saleh Suleiman Saleh, Abdullah Bashein, Nabil Enattah   +7 more
doaj   +2 more sources

Association between thiopurine S-methyltransferase polymorphisms and thiopurine-induced adverse drug reactions in patients with inflammatory bowel disease: a meta-analysis. [PDF]

PLoS ONE, 2015
Thiopurine drugs are well established treatments in the management of inflammatory bowel disease (IBD), but their use is limited by significant adverse drug reactions (ADRs).
Yue-Ping Liu, Hai-Yan Wu, Xiang Yang, Han-Qing Xu, Yong-Chuan Li, Da-Chuan Shi, Jun-Fu Huang, Qing Huang, Wei-Ling Fu   +8 more
doaj   +2 more sources

Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment response [PDF]

Pharmacogenomics and Personalized Medicine, 2017
Rachid Abaji,1 Maja Krajinovic2 1Department of Pharmacology, 2Departments of Pediatrics and Pharmacology, CHU Sainte-Justine Research Center, University of Montreal, Montreal, QC, Canada Abstract: The thiopurine S-methyltransferase (TPMT) gene encodes ...
Abaji R, Krajinovic M
doaj   +2 more sources

Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients [PDF]

Medicina, 2019
Background and Objectives: In patients with inflammatory bowel diseases (IBD), the use of azathioprine results in adverse events at a rate of 5% to 20%.
Davide Giuseppe Ribaldone, Alessandro Adriani, Gian Paolo Caviglia, Amedeo De Nicolò, Danilo Agnesod, Marco Simiele, Danila Riganò, Rinaldo Pellicano, Roberto Canaparo, Giovanni Di Perri, Antonio D’Avolio, Francesco Luzza, Ludovico Abenavoli, Giorgio Maria Saracco, Marco Astegiano   +14 more
doaj   +2 more sources

Clinical and Economic Impact of Expanded TPMT Testing to Prevent Thiopurine-Induced Myelosuppression in Australia: A Budget Impact Analysis. [PDF]

Clin Transl Sci
ABSTRACT Testing thiopurine methyltransferase (TPMT) enzyme activity or genotype prior to thiopurine prescribing is recommended to reduce the risk of moderate to severe—and potentially fatal—myelosuppression in poor or intermediate TPMT metabolizers. Despite this, only about one‐third of individuals prescribed thiopurines in Australia currently receive
Ianni BD, Ali MA, Yiu CH, Tan ECK, Lu CY.   +4 more
europepmc   +2 more sources

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update. [PDF]

Clin Pharmacol Ther
Thiopurine methyltransferase (TPMT) and Nudix hydrolase 15 (NUDT15) are key enzymes that catabolize thiopurines. Decreased or no‐function alleles in TPMT and NUDT15 are associated with reduced or no enzyme activity and predictive of pronounced adverse effects, including severe myelosuppression, that may occur among individuals treated with standard ...
Maillard M, Schwab M, Whirl-Carrillo M, Moyer AM, Suarez-Kurtz G, Pui CH, Stein CM, Klein TE, Spahn C, Kwon S, Hartono JL, de Boer NK, Ahmad T, Antillon-Klussmann FG, Caudle KE, Kato M, Yeoh AEJ, Schmiegelow K, Yang JJ.   +18 more
europepmc   +2 more sources

Pharmacogenomics of Thiopurine Drugs: A Bench-To-Bedside Success Story in Thailand. [PDF]

Clin Transl Sci
ABSTRACT Thiopurine drugs are the cornerstone treatment for many diseases such as acute lymphoblastic leukemia (ALL), organ rejection, inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and other autoimmune diseases.
Biswas M, John S, Murad MA, Sukasem C.
europepmc   +2 more sources

Genetic Determinants of Hematopoietic Toxicity Risk in Thai Pediatric Patients Undergoing 6-Mercaptopurine Treatment. [PDF]

Clin Transl Sci
ABSTRACT The nucleoside diphosphate‐linked moiety X‐type motif 15 (NUDT15) has been identified as a key genetic determinant of 6‐mercaptopurine (6‐MP)‐induced hematopoietic toxicity in populations with a high frequency of NUDT15 variants but a low frequency of thiopurine S‐methyltransferase (TPMT) variants.
Khaeso K, Chainansamit SO, Kuwatjanakul P, Komvilaisak P, Nakkam N, Suwannaying K, Vannaprasaht S, Dornsena A, Tassaneeyakul W.   +8 more
europepmc   +2 more sources

Unraveling Novel Genetic Determinants of Thiopurine Response Via TWAS. [PDF]

Clin Pharmacol Ther
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Thiopurines such as 6‐mercaptopurine (6MP) are essential in ALL maintenance therapy. However, dose‐limiting toxicities can significantly disrupt treatment. While genetic variants in TPMT and NUDT15 are known to affect thiopurine response, many patients with normal function ...
Bidoli C, Yang W, Karol SE, Lucafò M, Stocco G, Yang JJ.   +5 more
europepmc   +2 more sources